2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[3-(1-phenyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxopropyl]piperazine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 2-(3,4-dichlorophenyl)-4-(3,5-dimethylbenzoyl)-1-[3-(1-phenyl-4-oxo-1,3,8-triazaspiro[4.5]decan-8-yl)-1-oxopropyl]piperazine
• 英文别名: 8-[3-[2-(3,4-Dichlorophenyl)-4-(3,5-dimethylbenzoyl)piperazin-1-yl]-3-oxopropyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one
• 化学式: C₃₅H₃₉Cl₂N₅O₃
• 分子量: 648.632
• InChiKey: MRZUBGAQTOMLFJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  45
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  76.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Combination treatment for depression and anxiety
  申请人：Pfizer Inc.

  公开号：US20040006135A1

  公开（公告）日：2004-01-08

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g., a substance P receptor antagonist) in combination with an NK-3 antagonist agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an NK-3 antagonist.

  本发明涉及一种治疗哺乳动物（包括人类）的抑郁症或焦虑症的方法，该方法通过给哺乳动物（包括人类）注射一种中枢神经系统渗透的NK-1受体拮抗剂（例如物质P受体拮抗剂）与NK-3拮抗剂药物的组合来实现。本发明还涉及含有药学上可接受载体、中枢神经系统渗透的NK-1受体拮抗剂和NK-3拮抗剂的药物组合物。
• Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
  申请人：Pfizer Products Inc.

  公开号：EP1192952A2

  公开（公告）日：2002-04-03

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e.g. a substance P receptor antagonist) in combination with an NK-3 antagonist agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an NK-3 antagonist.

  本发明涉及一种治疗哺乳动物（包括人类）抑郁症或焦虑症的方法，其方法是向哺乳动物施用中枢神经系统穿透性NK-1受体拮抗剂（例如P物质受体拮抗剂）与NK-3拮抗剂联合制剂。它还涉及含有药学上可接受的载体、中枢神经系统穿透性 NK-1 受体拮抗剂和 NK-3 拮抗剂的药物组合物。
• COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS
  申请人：Pfizer Products Inc.

  公开号：EP1517708A1

  公开（公告）日：2005-03-30
• [EN] COMBINATION TREATMENT FOR DEPRESSION AND ANXIETY BY NK1 AND NK3 ANTAGONISTS<br/>[FR] TRAITEMENT COMBINE DE LA DEPRESSION ET DE L'ANXIETE A L'AIDE D'ANTAGONISTES NK1 ET NK3
  申请人：PFIZER PROD INC

  公开号：WO2004000355A1

  公开（公告）日：2003-12-31

  The present invention relates to a method of treating depression or anxiety in a mammal, including a human, by administering to the mammal a CNS-penetrant NK-1 receptor antagonist (e. g., a substance P receptor antagonist) in combination with an NK-3 antagonist agent. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a CNS-penetrant NK-1 receptor antagonist and an NK-3 antagonist.